Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABO2102 in KRAS Mutant Solid Tumors
NCT07455617Phase 1Recruiting
- Sponsor
- Abogen Bioscience
- Start
- Mar 2026
- Primary completion
- Jun 2029
- Modality
- Vaccine mRNA, mRNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of ABO2102 in solid tumor (2 arms), sponsored by Abogen Bioscience. Primary endpoints: Dose-Limiting Toxicities at 28 days, Adverse Events up to 90 days and 2 more. Started Mar 2026; status: recruiting.
02
Drugs
ABO2102
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07455617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07455617.